Kanerva A - Search Results

1

Adenoviral E4orf3 and E4orf6 proteins, but not E1B55K, increase killing of cancer cells by radiotherapy in vivo.

Liikanen I, Dias JD, Nokisalmi P, Sloniecka M, Kangasniemi L, Rajecki M, Dobner T, Tenhunen M, Kanerva A, Pesonen S, Ahtiainen L, Hemminki A. Liikanen I, et al. Among authors: kanerva a. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1201-9. doi: 10.1016/j.ijrobp.2010.05.037. Epub 2010 Sep 9. Int J Radiat Oncol Biol Phys. 2010. PMID: 20832189

2

Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D, Curiel DT. Haviv YS, et al. Among authors: kanerva a. Cancer Res. 2002 Aug 1;62(15):4273-81. Cancer Res. 2002. PMID: 12154029

3

CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.

Hakkarainen T, Hemminki A, Pereboev AV, Barker SD, Asiedu CK, Strong TV, Kanerva A, Wahlfors J, Curiel DT. Hakkarainen T, et al. Among authors: kanerva a. Clin Cancer Res. 2003 Feb;9(2):619-24. Clin Cancer Res. 2003. PMID: 12576427

4

Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.

Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT. Hemminki A, et al. Among authors: kanerva a. Cancer Res. 2003 Feb 15;63(4):847-53. Cancer Res. 2003. PMID: 12591736

5

A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.

Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP, Curiel DT. Hemminki A, et al. Among authors: kanerva a. Mol Ther. 2003 Feb;7(2):163-73. doi: 10.1016/s1525-0016(02)00049-7. Mol Ther. 2003. PMID: 12597904 Free article.

6

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.

Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT, Hemminki A. Kanerva A, et al. Mol Ther. 2003 Sep;8(3):449-58. doi: 10.1016/s1525-0016(03)00200-4. Mol Ther. 2003. PMID: 12946318 Free article.

7

A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.

Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Kanerva A, et al. Gene Ther. 2004 Mar;11(6):552-9. doi: 10.1038/sj.gt.3302181. Gene Ther. 2004. PMID: 14999227

8

Modified adenoviruses for cancer gene therapy.

Kanerva A, Hemminki A. Kanerva A, et al. Int J Cancer. 2004 Jul 1;110(4):475-80. doi: 10.1002/ijc.20129. Int J Cancer. 2004. PMID: 15122578 Review.

9

Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus.

Kanerva A, Zinn KR, Peng KW, Ranki T, Kangasniemi L, Chaudhuri TR, Desmond RA, Wang M, Takayama K, Hakkarainen T, Alfthan H, Stenman UH, Curiel DT, Hemminki A. Kanerva A, et al. Gene Ther. 2005 Jan;12(1):87-94. doi: 10.1038/sj.gt.3302387. Gene Ther. 2005. PMID: 15385953

10

Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.

Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A. Raki M, et al. Among authors: kanerva a. Gene Ther. 2005 Aug;12(15):1198-205. doi: 10.1038/sj.gt.3302517. Gene Ther. 2005. PMID: 15800658

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters